Safety, Tolerability and Partial Efficacy Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Pancreatic Cancer
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 7
- 试验地点
- 1
- 主要终点
- Number of participants experiencing clinical and laboratory adverse events (AEs)
研究概览
简要总结
This research study is evaluating a new type of pancreatic cancer vaccine called "Personalized Neoantigen Cancer Vaccine" as a possible treatment for advanced pancreatic cancer. The purpose of the clinical study is evaluating the safety, tolerability and partial efficacy of the personalized neoantigen cancer vaccine in the treatment of Chinese patients with advanced pancreatic cancer, so as to provide a new personalized therapeutic strategy for advanced pancreatic cancer patients.
It is known that cancer patients have mutations (changes in genetic material) that are specific to an individual patient and tumor. These mutations can cause the tumor cells to produce proteins that appear very different from the body's own cells. It is possible that these proteins used in a vaccine may induce strong immune responses, which may help the participant's body fight any tumor cells that could cause the cancer to come back in the future. The study will examine the safety of the vaccine when given at several different time points and will examine the participant's blood cells for signs that the vaccine induced an immune response.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must freely sign informed consent;
- •Aged 18 to 70 years old;
- •The expected survival period is more than 6 months;
- •ECOG score is 0 or 1;
- •Advanced pancreatic cancer diagnosed by Pathology and imageology;
- •Tumor cannot be excised by surgery, and multiline chemotherapy, radiation, targeted therapy fails, or other treatments cannot be tolerated;
- •At least one measurable lesions;
- •To be able to obtain sufficient tumor tissue samples and blood samples for analysis, or to have genomic/exon/transcriptional data of tumor tissues and normal tissues, and the data meet the analysis requirements;
- •The main organs function is normal, such as the heart, liver and kidney;
- •Haematological index:
- •neutrophil count≥1.5×10e9/L hemoglobin≥10g/dL platelet count≥100×10e9/L
- •Biochemical index:
- •Total bilirubin is less than or equal to 1.5 times the upper limit of normal value (ULN) AST and ALT is less than or equal to 2.5 times the upper limit of normal value Serum creatinine and urea nitrogen (BUN) is less than or equal to 1.5 times the upper limit of normal value
- •Pregnant, lactating women and women of child-bearing age must have a negative pregnancy test within 7 days before entering the group, and short-term have no fertility plan, and are willing to take protective measures (contraception or other birth control methods) before and during the clinical trial;
- •Good compliance, able to follow research protocols and follow-up procedures.
排除标准
- •Diagnosed as other malignant tumor;
- •There have been bone marrow or stem cell transplants;
- •No neoantigen was found in the sequencing data;
- •Systemic cancer treatment or other drugs under study were treated within 4 weeks prior to Individualized tumor targeted polypeptides treatment;
- •Received other polypeptide inoculation 4 weeks before treatment; Patients may not be vaccinated with other polypeptides 8 weeks after the last individualized tumor targeted polypeptides trentment;
- •Active bacterial or fungal infections identified clinically (>= level 2 of NCI-CTC edition 3);
- •Patients with HIV, HCV, HBV infection, severe asthma, autoimmune disease, immunodeficiency or treated with immunosuppressive drugs;
- •Severe coronary or cerebrovascular disease, or other diseases that the investigators considered should to be exclusion;
- •Drug abuse. Clinical, psychological or social factor result in affecting informed consent or research implementation;
- •Have a history of drug or polypeptide allergies, or people who are allergic to other potential immunotherapies.
结局指标
主要结局
Number of participants experiencing clinical and laboratory adverse events (AEs)
时间窗: 1 year
Objective Response Rate
时间窗: 2 years
次要结局
- Progression Free Survival(2 years)
- Overall Survival Rate(2 years)
研究者
Liu Yang
MD
Zhejiang Provincial People's Hospital